T he purpose of this study was to assess the effect of rosiglitazone on bioavailable, free and total testosterone levels in hypogonadal men with type 2 diabetes. Sixteen type 2 diabetic men with hypogonadism were studied before and after administration of rosiglitazone (8 mg/day) for six months, with assessments performed every two months on two consecutive days. We measured testosterone and sex hormone binding globulin (SHBG), visceral adiposity, high-sensitivity CRP (hs-CRP), lipids, microalbuminuria and blood pressure.
Introduction
Low testosterone levels in men are associated with reduced insulin sensitivity and vascular disease in type 2 diabetes. 1 Low testosterone levels in men have also been found to predict insulin resistance and subsequent development of type 2 diabetes. 2, 3 A high prevalence of hypogonadism has been reported in diabetic men. [4] [5] [6] [7] Circulating testosterone is present in three major fractions: free (2-3%), albumin-bound (20-50%) and sex hormone binding globulin (SHBG)-bound (50-80%). The free and albumin-bound testosterone fractions are biologically active and constitute the bioavailable testosterone (BT) whereas the testosterone that is bound to SHBG is tightly bound and considered to be inactive. SHBG levels correlate inversely with insulin resistance and obesity.
1 SHBG is low in some but not all diabetic men. 6 Free testosterone (FT) and BT levels are low in obese and diabetic men 6 and correlate inversely with the degree of obesity. 1 Even though the relationship between insulin resistance and low testosterone is well established, no studies have examined the effects of reduction of insulin resistance, using insulin-sensitising agents, on testosterone and SHBG levels in diabetic men. The purpose of this study was to investigate the effect of the insulin-sensitising agent rosiglitazone on BT, FT, total testosterone (TT) and SHBG levels in hypogonadal men with type 2 diabetes. We also examined the effects of rosiglitazone on visceral adiposity, body mass index (BMI), percentage body fat, fasting lipids, microalbuminuria, high-sensitivity C-reactive protein (hs-CRP) and blood pressure.
Materials and methods
This was a longitudinal study of six months' duration in which men with type 2 diabetes and hypogonadism were given rosiglitazone (Avandia ® ) 8 mg/day. Hypogonadism was defined as two TT measurements < 12 nmol/L (before 10 6, 8 Exclusion criteria were: CRP > 10 mg/L, hepatic impairment, heart failure, elevated prostate specific antigen (PSA) and hormone or insulin therapy.
Assessments were performed every two months on two consecutive days and mean testosterone levels were determined. All concomitant medications were continued throughout the study period without dose adjustment. Subjects were naïve to thiazolidinediones.
Assessments were made between 8 am and 10 am after an overnight fast as testosterone levels have a diurnal variation with a peak in the morning, reaching a nadir in the evening. BMI, waist circumference (WC), waist/hip ratio (WHR), percentage body fat (by Tanita BF-300 body fat analyser) and blood pressure were recorded. TT, SHBG and hs-CRP were measured by ELISA (DRG Instruments GmbH, Germany); fasting lipids (Olympic Diagnostics, Hamburg, Germany) and urine microalbumin (Olympic Diagnostics, Hamburg, Germany) were assayed. FT was calculated using the Vermeulen formula 9 and BT by the Morris formula. 10 Data were analysed using ANOVA and considered statistically significant at p<0.05.
Results
Twenty patients completed the study. Four were withdrawn because of protocol violation. Their mean age was 52.38+2.6 years (range 37-75). Five patients had primary, two secondary, and nine mixed hypogonadism (normal LH) (luteinising hormone). TT, SHBG, FT and BT levels were all significantly increased with rosiglitazone treatment, with a maximum effect at four months ( There was a significant reduction in hs-CRP levels and an improvement in glycaemic control. Five patients had microalbuminuria at baseline (mean 80+32.25 mg/L) and in all these patients microalbuminuria testing was negative after six months. One patient had frank proteinuria (300 mg/L), which decreased to 114.3 mg/L after six months.
Discussion
This pilot study demonstrates that rosiglitazone increases TT and, more importantly, FT and BT in hypogonadal men with type 2 diabetes. It is generally perceived that low testosterone levels found in diabetic men occur as a consequence of low SHBG levels. Rosiglitazone increased SHBG levels, possibly by improving hepatic insulin sensitivity, but this does not alone explain fully the rise in TT. We have shown that Key: hs-CRP = high-sensitivity C-reactive protein; HbA 1C = glycosylated haemoglobin; FBG = fasting blood glucose; TT = total testosterone; SHBG = sex hormone binding globulin; T = testosterone; BMI = body mass index; HDL = high-density lipoprotein; LDL = low-density lipoprotein; Bio = bioavailable rosiglitazone boosts the biologically active fraction of circulating testosterone. The increases in total and bioactive testosterone are small but significant and demonstrate that low SHBG levels are not wholly responsible for the high prevalence of hypogonadism found in patients with type 2 diabetes. This is confirmed by studies that have shown approximately one third of men with type 2 diabetes were hypogonadal by FT assayed by equilibrium dialysis and BT measured by ammonium sulphate precipitation. 6, 7 Rosiglitazone, as in this study, is known to increase the BMI. However, we have shown that it reduces visceral adiposity (assessed by WC and WHR) without changing the overall percentage of body fat. Thiazolidinediones have been demonstrated to increase subcutaneous but not visceral fat as measured by magnetic resonance imaging (MRI). 11, 12 One hypothesis to explain why rosiglitazone increases BT and FT could be based on the hypogonadal-obesityadipocytokine cycle. 1, 13 Reduction in visceral fat mass decreases aromatase activity and hence the breakdown of testosterone. The rising level of testosterone then inhibits lipoprotein lipase enzyme activity in visceral fat, reducing fatty acid uptake and decreasing visceral adipose tissue mass.
14 This in turn results in further increases in testosterone concentrations. It is not clear whether the reduction in adiposity occurs directly as a result of rosiglitazone or via increased testosterone bioactivity. Testosterone replacement in hypogonadal men with diabetes improves insulin sensitivity, glycaemic control and waist circumference. 15 The beneficial effects of rosiglitazone on testosterone and visceral adiposity were associated with improved glycaemic control, decreased urinary albumin excretion and hs-CRP. The effects on lipids and blood pressure were consistent with reported data. We appreciate that our pilot study was nonblinded and non-placebo controlled as we were unable to obtain placebo. However, total, free and bioavailable testosterone fractions were measured on two consecutive days so that abnormal and borderline values could be confirmed.
In conclusion, we have shown that rosiglitazone therapy in hypogonadal men with type 2 diabetes increases both SHBG-bound as well as free and bioavailable testosterone. These effects are small but significant and imply that the low levels of testosterone found in the male diabetic population cannot be accounted for by low SHBG levels alone.
